Purpose: Recent reports have suggested that fluid restriction as part of Enhanced Recovery after Surgery (ERAS) pathways may increase the risk of AKI in radical cystectomy (RC) patients. We sought to evaluate the impact of ERAS initiation on AKI incidence at a high-volume tertiary care center.
Materials And Methods: We performed a retrospective review of our IRB approved database to identify patients receiving RC from 2010 to 2019. ERAS was initiated at our institution in October 2016. Acute kidney injuries were graded according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria and must have occurred within 7 days of indexed RC. Estimated glomerular filtration rate (eGFR) was captured at baseline, 1, 3, 6, and 12 months respectively. Categorical variables were compared with the Pearson-Chi square test. Quantitative variables were analyzed with the Wilcoxon-Rank sum test. Multivariable binary logistic regression and interaction analysis was used to identify predictors of AKI.
Results: Twelve hundred patients were included. Twenty-two percent of patients experienced an AKI within 7 days. Patients in the ERAS cohort experienced less AKIs after RC (18% vs. 25%, P = 0.003). When adjusting for year of surgery, ERAS was not a significant predictor for AKI on multivariable analysis (OR: 0.87, P = 0.73). On interaction analysis, during the ERAS era, intracorporeal robot-assisted radical cystectomy (iRARC) was associated with decreased odds of AKI (OR: 0.39, P = 0.034). There were no significant differences in eGFR at 12 months postoperatively (P = 0.16).
Conclusion: Unlike previous reports, ERAS initiation was not associated with increased risk of AKI at a tertiary care high-volume center.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.urolonc.2022.07.004 | DOI Listing |
Vet Radiol Ultrasound
January 2025
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
A young, intact, female, American Bulldog was presented for hemorrhagic vaginal discharge. Anemia, thrombocytopenia, leukocytosis with neutrophilia, azotemia, and electrolyte disturbances were detected in the bloodwork. A urachal diverticulum with concurrent uterine distention was identified by ultrasonography and CT.
View Article and Find Full Text PDFUrology
January 2025
Columbia University Irving Medical Center, Department of Urology. Electronic address:
Int Urol Nephrol
January 2025
Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, No. 82 Cuiyingmen, Chengguan District, Lanzhou, Gansu, China.
Purpose: To evaluate the impact of maximal transurethral resection of bladder tumor (TURBT) on perioperative outcomes following radical cystectomy (RC).
Methods: This study included 310 patients who underwent RC for the diagnosis of bladder urothelial carcinoma. Of these, 146 patients had a history of maximal TURBT (TURBT group) and 164 did not (non-TURBT group).
Int J Med Sci
January 2025
Department of Urology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
: Diabetes mellitus (DM) is associated with worse surgical outcomes, and is a risk factor for bladder cancer and subsequent oncological outcomes. This study evaluated outcomes robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) in patients with DM. : Data of adults ≥ 18 years old with DM who underwent radical cystectomy were extracted from the United States National Inpatient Sample database 2005-2018.
View Article and Find Full Text PDFPurpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma and muscle-invasive bladder cancer. This study evaluates the safety and efficacy of tislelizumab combined with low-dose nab-paclitaxel in extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC).
Patients And Methods: TRUCE-02 was a single-arm phase 2 trial that included 63 patients with visually incomplete resection and/or high-volume high-grade T1 tumors (with or without carcinoma in situ), who were ineligible for or declined radical cystectomy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!